– Scientific collaborators at Stanford University will present data on an imaging and treatment regimen demonstrating the microglial targeting of [18F]OP-801 in a mouse model
– First patient was enrolled as part of a two-stage Phase 2 study evaluating Ashvattha’s subcutaneous (SC) anti-VEGF wet AMD and DME candidate, D-4517.2 –
– Data highlights [18F]OP-801’s differentiated imaging profile as a promising tracer for visualizing the progression of neuroinflammation – REDWOOD CITY, Calif., August 1, 2022 –
– Data showed OP-101 delivered intravenously may have the potential to treat systemic inflammation and neuronal injury, reducing morbidity and mortality in hospitalized patients with
– Scientific collaborators at Stanford University will present preclinical data on the sensitivity of [18F]OP-801 in comparison to TSPO-PET for detecting early-stage neuroinflammation – REDWOOD
Scientific collaborators at Indiana University School of Medicine presented preclinical data showing Ashvattha’s hydroxyl dendrimers (HDs) were selectively taken up only within tumor-associated microglia/macrophages in
– Scientific collaborators at Indiana University School of Medicine will present preclinical data demonstrating Ashvattha’s hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform
REDWOOD CITY, Calif., May 5, 2022 – Ashvattha Therapeutics, (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced that Jeffrey Cleland, Ph.D.,
Data showed single subcutaneous doses of D-4517.2 were safe and well tolerated in healthy subjects D-4517.2 exposure in healthy subjects translates to efficacious doses in
Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced it has secured $69 million in a Series B financing and in a separate agreement entered an exclusive licensing deal with Huadong Medicine.